ArticleJournal of clinical medicine2022
Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Heart Failure in Patients with Sarcopenia: Systematic Review and Meta-Analysis.Annals of geriatric medicine and research · 2025Pooled it
- Diagnosis of heart failure with preserved ejection fraction: a systematic narrative review of the evidence.Heart failure reviews · 2024Pooled it
- Real-world study of finerenone in patients with heart failure with preserved ejection fraction in Spain.BMC cardiovascular disorders · 2026Observational
- Sex Differences in Heart Failure Epidemiology and Clinical Characteristics in Spain: A Nationwide Population-Based Study.Journal of clinical medicine · 2026Article
- Heart Failure in Older Adults: Real-World Outcomes and Patient Profiles by Admission Service and Sex.Journal of clinical medicine · 2026Article
- Peptide and Protein Tags for the Half-Life Extension of Therapeutic Agents: A Review Article.The protein journal · 2026Review
- Efficacy and Safety of Vericiguat in a Real-life Population with Heart Failure after 1 Year of Treatment: The VERITA Study.Cardiac failure review · 2026Article
- Prevalence and characterization of heart failure in Aragon, Spain (ICAR study).Frontiers in cardiovascular medicine · 2026Article
- Heart failure types and predictors of 30-day rehospitalisation among patients aged ≥ 60 years with acute heart failure: a multicentre prospective study in Vietnam.BMC cardiovascular disorders · 2025Article
- Epidemiological Trends of Heart Failure Subtypes, Characteristics, and Outcomes Within Inpatient Hospitalizations.Cardiology research · 2025Article
- Improvement initiatives in the diagnostic process of heart failure: a scoping review.Frontiers in cardiovascular medicine · 2025Review
- Life-course obesity and heart failure: a two-sample Mendelian randomization study.Internal and emergency medicine · 2025Article
- Reversed sex disparities in heart failure mortality in Spain, 2000-2023: a population-based analysis of older adults.Frontiers in public health · 2025Article
- Quality of Care among Post-discharge Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) at the Outpatient Department (OPD) of a Tertiary Center.Acta medica Philippina · 2025Article
- Clinical profile, associated events and safety of vericiguat in a real-world cohort: The VERITA study.ESC heart failure · 2024Observational
- Characteristics and outcomes of heart failure in Japan: A hospital-based administrative database analysis.ESC heart failure · 2024Article
- Effect of severity and etiology of chronic kidney disease in patients with heart failure with mildly reduced ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Global epidemiology of heart failure.Nature reviews. Cardiology · 2024Review
- Trends in cardiovascular disease among Inuit in Greenland from 1994 to 2021.Atherosclerosis plus · 2024Article
- Progress of patients hospitalized with acute heart failure treated with empagliflozin.Journal of comparative effectiveness research · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To estimate the prevalence, incidence, and describe the characteristics and management of patients with heart failure with preserved (HFpEF), mildly reduced (HFmrEF), and reduced ejection fraction (HFrEF) in Spain. Methods: Adults with ≥1 inpatient or outpatient HF diagnosis between 1 January 2013 and 30 September 2019 were identified through the BIG-PAC database. Annual incidence and prevalence by EF phenotype were estimated. Characteristics by EF phenotype were described in the 2016 and 2019 HF prevalent cohorts and outcomes in the 2016 HF prevalent cohort. Results: Overall, HF incidence and prevalence were 0.32/100 person-years and 2.34%, respectively, but increased every year. In 2019, 49.3% had HFrEF, 38.1% had HFpEF, and 4.3% had HFmrEF (in 8.3%, EF was not available). Compared with HFrEF, patients with HFpEF were largely female, older, and had more atrial fibrillation but less atherosclerotic cardiovascular disease. Among patients with HFrEF, 76.3% were taking renin-angiotensin system inhibitors, 69.5% beta-blockers, 36.8% aldosterone antagonists, 12.5% sacubitril/valsartan and 6.7% SGLT2 inhibitors. Patients with HFpEF and HFmrEF took fewer HF drugs compared to HFrEF. Overall, the event rates of HF hospitalization were 231.6/1000 person-years, which is more common in HFrEF patients. No clinically relevant differences were found in patients with HFpEF, regardless EF (50- < 60% vs. ≥60%). Conclusions: >2% of patients have HF, of which around 50% have HFrEF and 40% have HFpEF. The prevalence of HF is increasing over time. Clinical characteristics by EF phenotype are consistent with previous studies. The risk of outcomes, particularly HF hospitalization, remains high, likely related to insufficient HF treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.